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Background: Defective copper regulation is implicated as a causative mechanism of organ damage in diabetes.
Treatment with trientine, a divalent-copper-selective chelator, improves arterial and renal structure/function in
diabetes, wherein it also ameliorates left-ventricular (LV) hypertrophy. However, direct in vivo evidence that trientine
can improve cardiac function in heart failure has hitherto been lacking.
Methods: To determine whether trientine treatment could improve in vivo outcome, we measured cardiac
function in groups of trientine-treated diabetic (TETA-DIA), non-drug-treated diabetic (DIA) and sham-treated
control (SHAM) rats, by using in vivo high-field cardiac magnetic-resonance imaging (cMRI) and an ex vivo isolated-
perfused working heart method. Forty age-matched animals underwent a cMRI scan after which 12 were
randomized to the SHAM group and 28 underwent streptozotocin-injection; of these, 25 developed stable diabetes,
and 12 were then randomized to receive no treatment for 16 weeks (DIA) and the other 13 to undergo 8-weeks’
untreated diabetes followed by 8-weeks’ drug treatment (TETA-DIA). Animals were studied again by cMRI at 8 and
16 weeks following disease induction, and finally by measurement of ex vivo cardiac function.
Results: After eight weeks diabetes, rats (DIA/TETA-DIA) had developed significant impairment of LV function, as
judged by impairment of ejection fraction (LVEF), cardiac output (CO), and LV mass (LVM)/body-mass (all P < 0.001),
as well as other functional indexes. LVEF, CO (both P < 0.001) and the other indexes deteriorated further at
16 weeks in DIA, whereas trientine (TETA-DIA) improved cardiac function by elevating LVEF and CO (both P < 0.001),
and also partially reversed the increase in LVM/body-mass (P < 0.05). In ex vivo hearts from DIA, the CO response to
increasing preload pressure was deficient compared with SHAM (P < 0.001) whereas the preload-CO relationship
was significantly improved in TETA-DIA animals (P < 0.001).
Conclusions: Trientine treatment significantly improved cardiac function in diabetic rats with substantive LV
impairment. These results implicate impaired copper regulation in the pathogenesis of impaired cardiac function
caused by diabetic cardiomyopathy, and support ongoing studies of trientine treatment in patients with heart
failure.
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Cardiovascular disease is the leading cause of morbidity
and mortality in diabetes, but effective treatments for
established heart failure in diabetes are limited [1-3].
The prognosis of heart failure is particularly poor in
patients with type-2 diabetes (T2DM)a, the most com-
mon form of this disease [4]. This poor prognosis per-
sists in spite of best available treatment with existing
classes of medications including glucose-lowering, anti-
hypertensive, and lipid-lowering drugs, as well as beta-
blockers, angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers (ARBs) amongst others.
Therefore, new and improved therapeutic approaches
for heart failure in diabetes are urgently required.
We have previously identified a pathogenetic disorder
of copper regulation that occurs in both type-1 diabetes
(T1DM) and T2DM [5,6], and have shown that it is a
probable cause of the cardiovascular and renal complica-
tions of diabetes [5,7-9] and a new target for pharmaco-
logical intervention [5,6,10]. We have also shown that
trientine (triethylenetetramine dihydrochloride) [10], acts
in vivo as a Cu(II)-selective chelator that can prevent or
ameliorate cardiovascular and renal disease in diabetic
rats [5,8,11]. Trientine exerts its effects in diabetic ani-
mals and patients without lowering blood pressure or
blood glucose [5,12].
We have extended our studies to patients with T2DM
[6,10,12,13], in whom trientine treatment significantly
improves LV hypertrophy [12] and indexes of metabolic
regulation [6].
Triethylenetetramine (also named TETA or trien) is
the pharmacologically active moiety in trientine. Its
structure closely resembles those of the endogenous
polyamines, spermine and spermidine [14,15]. Trientine
is a well-tolerated orally-active drug which acts as a Cu
(II)-selective chelator in humans [6,10] and has been
employed for more than two decades for the second-line
treatment of Wilson’s disease in penicillamine-intolerant
patients [16-18]. It has been linked to occasional cases
of anemia [19] and thrombocytopenia [20] in patients
with Wilson’s disease.
Diabetic animals show signs consistent with dysregula-
tion of systemic copper homeostasis. These manifest in
organs including the heart, arteries, kidneys and nerves
[21]. In normal physiology, copper is present in one of
two valence states: univalent copper, Cu(I), which is said
to comprise ~95% of total body copper and is the pre-
dominant intracellular form, and Cu(II) which comprises
the remainder and is mainly present in the extracellular
space; in quoting this relative distribution of copper
valence states, we follow Fraústo da Silva and Williams
[22]. Infusion of trientine has revealed that systemic Cu
(II) is significantly elevated in diabetic rats [5,8,9]. Non-
clinical [5] and clinical studies [6,12,14] have shown thatdiabetic rats and patients display signs of a systemic cop-
per overload state, which is characterized by the follow-
ing characteristics: elevations in basal urinary copper
excretion; elevated copper balance; increased urinary Cu
(II) excretion following administration of trientine; and
increased circulating superoxide dismutase activity. Fur-
thermore, levels of Cu(II) extracted from the coronary
arteries by trientine infusion are also significantly
increased in diabetic rats [5]. Trientine binds selectively
to Cu(II) but not to Cu(I) so elevations in trientine-
chelatable copper are consistent with elevated Cu(II) [5,21].
In vivo data demonstrating trientine-mediated improve-
ments in cardiac function in diabetic animals with heart
failure have hitherto been lacking. Here we report results
of a study in which we have tested the hypothesis that
orally-administered trientine can improve in vivo cardiac
function in diabetic rats with established heart failure.
Materials and methods
Animals and treatments
This study was approved by the University of Auckland
Animal Ethics Committee. Its performance was consist-
ent with principles described in the Guide for the Care
and Use of Laboratory Animals [23] and the ARRIVE
guidelines for the reporting of animal research [24].
Forty male Wistar rats, whose age was between six
and seven weeks and whose average body-weight was
256 ± 37 g mean (± SD) at commencement, were sourced
from the Integrated Physiology Unit (School of Biological
Sciences, University of Auckland) and entered into the study.
They were housed (12:12-h light–dark cycle; temperature
22.5°C [range: 20–26]; humidity 50-70%) in like-pairs
with ad libitum access to water and food (Teklad 2018,
Harlan Laboratories, Placentia, CA). Study-group charac-
teristics were as summarized in Table 1, and the work-
flow followed during the in vivo part of the study was as
shown in Figure 1.
After the first cMRI scan (at Week 0), 28 animals were
randomly selected to receive a single intravenous tail-
vein injection of streptozotocin (STZ, Sigma; 55 mg/kg
body-weight) in isotonic saline as described previously
[5], and tail-vein blood-glucose values monitored weekly
thereafter. The remaining 12 rats were designated as
healthy controls (SHAM) and sham-treated by injection
of an equivalent volume of isotonic saline (vehicle) only.
Twenty-five of the 28 STZ-treated rats became stably dia-
betic, as determined by repeated blood glucose values >
11 mM. Of these, 12 were then randomized to the un-
treated diabetic group (DIA) and 13 to the TETA-treated
diabetic group (TETA-DIA). Data from the 37 animals
in the 3 study groups, comprising 12 controls (SHAM),
12 untreated-diabetic (DIA) and 13 drug-treated diabet-
ic (TETA-DIA) were collected and have been analysed
herein.
Table 1 Relevant characteristics and between-group comparisons at baseline (Week 0)
Variable Control (SHAM) Diabetic (DIA) TETA-treated Diabetic (TETA-DIA) P-value †
Strain Wistar Wistar Wistar -
Age (weeks) 6-7 6-7 6-7 -
Number (% male)* 12 (100) 12 (100) 13 (100) -
Body-weight (g) 271 (255–287) 280 (257–302) 255 (239–271) NS
Blood glucose (mM) 5.1 (4.9-5.2) 6.0 (5.7-6.3) a 6.7 (5.9-7.5) a < 0.001
Heart rate (bpm) 380 (370–389) 376 (364–388) 393 (381–401) 0.059
LVM (mg) 569 (525–614) 566 (521–610) 528 (493–562) NS
LVM/BW (mg/g) 2.12 (1.89-2.35) 2.04 (1.87-2.22) 2.08 (1.95-2.21) NS
CO (ml/min) 133 (120–146) 139 (125–152) 137 (130–140) NS
CO/BW (ml/min.g) 0.50 (0.44-0.55) 0.50 (0.43-0.58) 0.54 (0.50-0.59) NS
CO/LVM (ml/min.mg) 0.24 (0.21-0.26) 0.25(0.23-0.26) 0.26(0.24-0.29) NS
LVEF (%) 72.2 (69.6-74.9) 74.7 (72.9-76.5) 73.4 (71.4-75.5) NS
LVEDV (μl) 485 (446–525) 494 (440–549) 476 (456–496) NS
LVEDV/LVM (μl/mg) 0.86 (0.78-0.94) 0.87 (0.82-0.93) 0.91 (0.85-0.98) NS
LVESV (μl) 134 (120–149) 125 (108–143) 126 (116–136) NS
LVESV/LVM (μl/mg) 0.28 (0.25-0.30) 0.25 (0.24-0.27) 0.27 (0.25-0.29) NS
Stroke Vol (μl) 352 (317–386) 369 (329–410) 350 (330–370) NS
Stroke Vol/LVM (μl/mg) 0.62 (0.56-0.69) 0.65 (0.61-0.70) 0.67 (0.61-0.73) NS
Variables with bracketed numbers are means (± 95% CI) except for number (%) *: a, significantly greater than corresponding SHAM value.
†One-way ANOVA with post-hoc Tukey’s tests as indicated. Abbreviation: bpm, beats/min; NS, not significant; -, not tested.
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underwent a second cMRI study. Thereafter, the TETA-
DIA animals were continuously treated with trientine
(Fluka) at 20 mg/day-rat via their drinking water for the
subsequent 8-week period, whereas the DIA rats receive
water without drug. At the end of Week 16, all rats
underwent a third cMRI scan after which they were
anesthetized (isoflurane), heparinized (200 I.U./kg i.v.),
and their hearts excised. Ex vivo indexes of cardiac func-
tion were then determined in isolated-perfused working
heart preparations by using established methods [5,25].Figure 1 Flow chart illustrating the make-up and disposition of the st
this study.In vivo cardiac magnetic resonance imaging
Cardiac MR images were acquired just before the time
of diabetes induction during experimental Week 0, and
at the ends of Weeks 8 and 16 by using a Varian 4.7-
Tesla horizontal-bore magnet controlled by a Unity
Inova spectrometer (Palo Alto, CA, USA). Animals were
anesthetized with 2-4% (v/v) isoflurane in air adjusted
according to respiratory monitoring, with subsequent
placement of electrocardiogram (ECG)-, respiration- and
temperature-monitoring electrodes (SAII, Stony Brook,
NY), and mounting in a 72-mm inner-diameter circularly-udy groups during the 16-week course of the in vivo part of
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Core body temperature was maintained at 35-38°C by
directing a regulated stream of warm air over the animal,
and heart rate was recorded throughout the study.
Following acquisition of scout images, a cardiac- and
respiration-gated T1-weighted gradient-echo cine study
was acquired in the cardiac short-axis orientation span-
ning from the apex to the base of the LV (Repetition
time, TR = 2 × R-R interval, ~ 280–360 msec; echo time,
TE = 2.2 msec, cardiac phases = 20, flip angle = 20°, slices =
6, thickness = 2 mm, averages = 2, field of view = 60 ×
60 mm, matrix = 128 × 128, gap between slices = 0.6-
1.0 mm according to the size of the heart). A second cine
study was then performed in the cardiac long-axis view
using the same acquisition parameters (slices = 3, and
oriented to give 2-, 3- and 4-chamber views). Cardiac
short-axis images were then generated by using the multie-
cho Dixon fat and water separation method [26,27] (TR =
1000 msec, TE = 20 msec and matrix = 256 × 128).
Left-ventricular end-diastolic volume (LVEDV), left-
ventricular end-systolic volume (LVESV) and left-
ventricular mass (LVM) were determined by manual
contouring of the endocardial and epicardial borders
of the short axis cine images using ImageJ (National
Institutes of Health, v1.44i; http://rsb.info.nih.gov/ij),
and LV-wall volume and LVM were calculated by slice sum-
mation (LVM= (epicardial – endocardial volume) × density
of 1.05 g/ml) as previously described [5,28]. A similar
method was used to estimate the cardiac-fat volume in the
Dixon images by using ImageJ. Left-ventricular ejection frac-
tion (LVEF) was calculated as (LVEDV-LVESV)/LVEDV and
LV cardiac output (CO) as (LVEDV-LVESV) × heart rate.Isolated-perfused working-heart model
Ex vivo measurements of systolic function were per-
formed following excision of isolated-perfused working
hearts at the end of Week 16 in the three treatment
groups, by using our previously described methods [5,7].
In brief, excised hearts were immersed in Krebs-
Henseleit bicarbonate buffer (KHB) at 4°C. Retrograde
(Langendorff ) perfusion was initially established (KHB,
37°C, gassed with O2:CO2 95:5 vol/vol), after which
working-mode perfusion was instituted at physiological
values of preload pressure and heart-rate (preload, 10
cmH2O; afterload, 55.9 mmHg; with pacing at 300
beats/min (Digitimer)) [5,29]. Intra-chamber LV pressure
(SP855; AD Instruments), aortic pressure (PX23XL,
Stratham Gould), and aortic (Transonic T206) and cor-
onary flows were measured (SP855) (Powerlab16s, ADI)
and CO calculated. Atrial filling pressure was then
decreased, to 5 cmH2O, and thereafter increased, in
seven steps of 2.5 cmH2O to 20 cmH2O [final], and 1-
min averages were extracted.Statistical analysis
Data in tables have generally been expressed as means
(± 95% CI). The significance of between-group differ-
ences at specific time-points has been assessed by the
fitting of ANOVA models (with post-hoc Tukey’s tests
as required) and of time-dependent effects by linear
mixed-effects modelling (LME) (Splus v8.1; Spotfire,
TIBCO, Somerville, MA). P-values of < 0.05 have been
adjudged significant. P-values of 0.05 ≤ P ≤ 0.10 have
been included in tables if they occurred.Results
Effects of diabetes and trientine treatment on blood
glucose and body-weight
Work-flows were as shown in Figure 1 and data and
statistical analysis as summarized in Tables 1, 2, 3, 4. De-
scriptive data were comparable in all groups at baseline,
except for a modest albeit statistically-significant differ-
ence in blood glucose levels (Table 1).
All diabetic rats that were randomized remained dia-
betic throughout the 16-week experimental period
(Figure 2A, Tables 2, 3, 4). At Weeks 8 and 16, DIA and
TETA-DIA rats had much higher glucose values than
SHAM (P < 0.0001) and trientine had no effect on glu-
cose levels (Tables 3 and 4).
Body-weight did not differ between experimental
groups at baseline (Table 1). Sham-treated control rats
gained significant body-weight during the 16-week experi-
mental period whereas weight-gain in diabetic rats was
much more limited (Figure 2B and Tables 2, 3, 4). SHAM
rats had significantly higher body-weights than DIA and
TETA-DIA animals at Weeks 8 and 16 (both P < 0.001;
Tables 2, 3, 4). Trientine had a modest effect on the body-
weight:time interaction in diabetic animals consistent with
the slight amelioration of diabetes-evoked impairment of
weight gain (P = 0.035, LME; Table 4).Diabetes-evoked left-ventricular impairment
Diabetic rats developed LV impairment that was evident
at Week 8. This was characterised by impairment in in-
dexes of cardiac structure/function, including LVM/
body-weight, CO, CO/LVM, LVEF, LVEDV, LVESV/
LVM, stroke volume and stroke volume/LVM (all P <
0.0001 except the last, which was P = 0.001) (Table 2).
The effects of diabetes were comparable in DIA and
TETA-DIA groups, save that the lowering of heart rate
was more severe in DIA, whereas the depression of
stroke volume was more pronounced in TETA-DIA
(Table 2). LV function in DIA deteriorated further at
Week 16 (Tables 2, 3, 4).The between-group difference
in diabetes-induced bradycardia persisted at Week 16
and trientine had no effect on heart rate (Tables 2, 3, 4).
Table 2 Between-group comparisons at Week 8: effects of diabetes on cardiac function directly before commencement
of TETA treatment
Variable Control (SHAM) Diabetic (DIA) TETA-treated diabetic (TETA-DIA) P-value †
Body-weight (g) 440 (425–455) 319 (298–340) a 326 (305–347) a < 0.0001
Blood glucose (mM) 5.1 (4.7-5.6) 29.5 (27.0-32.1) a 28.1 (25.3-30.8) a < 0.0001
Heart Rate (bpm) 401 (391–411) 322 (311–332) a 343 (335–352) a, b < 0.0001
LVM (mg) 776 (731–820) 687 (651–723) a 710 (668–751) a 0.006
LVM/BW (mg/g) 1.76 (1.68-1.85) 2.17 (2.01-2.33) a 2.19 (2.07-2.31) a < 0.0001
CO (ml/min) 200 (194–206) 135 (127–144) a 135 (129–140) a < 0.0001
CO/LVM (ml/min.mg) 0.26 (0.24-0.28) 0.20 (0.18-0.21) a 0.19 (0.18-0.20) a < 0.0001
LVEF (%) 73.7 (71.0-76.4) 68.2 (67.0-69.5) a 66.3 (64.5-68.0) a < 0.0001
LVEDV (μl) 679 (651–706) 617 (584–651) a 591 (572–610) a < 0.0001
LVEDV/LVM (μl/mg) 0.88 (0.84-0.92) 0.90 (0.85-0.95) 0.84 (0.79-0.89) NS
LVESV (μl) 179 (157–202) 196 (183–209) 199 (189–210) NS
LVESV/LVM (μl/mg) 0.26 (0.24-0.29) 0.32 (0.31-0.33) a 0.34 (0.32-0.35) a < 0.0001
Stroke Vol (μl) 500 (480–520) 421 (396–446) a 392 (374–411) a < 0.0001
Stroke Vol/LVM (μl/mg) 0.65 (0.61-0.68) 0.61 (0.58-0.65) 0.56 (0.52-0.59) a, b 0.001
Values are means (± 95% CI). † One-way ANOVA with post-hoc Tukey’s tests as necessary: a, significantly different from corresponding SHAM value; b, significantly
different from corresponding DIA value. Abbreviations: bpm, beats per minute; NS, not significant.
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and the percentage of cardiac fat volume to myocardial
volume
We have employed LVM normalized to BW (LVM/BW)
as an index of body-mass, as in previous studies [5].
Some workers prefer the indexing of LVM to tibial
length, but others prefer LVM/BW. The improved dis-
crimination of the effects of drug treatment on LVM/
BW as opposed to unindexed LVM observed in this
study (Tables 2, 3, 4) provides support for the use ofTable 3 Between-group comparisons at Week 16: effects of 8
cardiomyopathy
Variable Control (SHAM) Diabetic (D
Body-weight (g) 489 (466–511) 313 (283–34
Blood glucose (mM) 4.7 (4.4-5.1) 28.8 (27.2-3
Heart Rate (bpm) 396 (384–408) 317 (306–32
LVM (mg) 785 (744–826) 732 (698–76
LVM/BW (mg/g) 1.61(1.51-1.71) 2.38 (2.18-2
CO (ml/min) 222 (213–232) 130 (123–13
CO/LVM (ml/min.mg) 0.28 (0.26-0.30) 0.18 (0.17-0
LVEF (%) 72.9 (70.7-75.1) 62.6 (60.6-6
LVEDV (μl) 770 (753–788) 656 (628–68
LVEDV/LVM (μl/mg) 0.99 (0.94-1.03) 0.90 (0.85-0
LVESV (μl) 209 (192–225) 246 (229–26
LVESV/LVM (μl/mg) 0.27 (0.25-0.29) 0.37 (0.35-0
Stroke Vol (μl) 562 (540–585) 410 (388–43
Stroke Vol/LVM (μl/mg) 0.72 (0.68-0.76) 0.56 (0.53-0
Values are means (± 95% CI). † One-way ANOVA with post-hoc Tukey’s tests as nece
different from corresponding DIA value. Abbreviation: bpm, beats per minute.LVM/BW. Here, variables pertaining to cardiac function,
including CO, LVEDV, LVESV and stroke volume, have
been normalized to LVM, and our evidence clearly indi-
cates that CO/LVM is preferable to CO/BW as a
normalization procedure (Tables 1, 2, 3, 4, Figure 3).
Changes in the LVM-to-body-weight ratio (LVM/BW)
[30] over the experimental period are shown (Figure 2C
and Tables 1, 2, 3, 4). At the outset, all three experimen-
tal groups had similar LVM/BW ratios. As they aged, the
LVM/BW ratio in SHAM rats fell progressively. By-weeks TETA treatment on cardiac function in diabetic
IA) TETA-treated diabetic (TETA-DIA) P-value †
4) a 346 (323–368) a < 0.0001
0.4) a 28.0 (25.7-30.4) a < 0.0001
8) a 336 (326–346) a, b < 0.0001
7) 737 (688–767) 0.049
.57) a 2.12 (1.98-2.27) a, b < 0.0001
6) a 159 (151–167) a, b < 0.0001
.19) a 0.22 (0.21-0.23) a, b < 0.0001
4.6) a 71.1 (68.8-73.4) b < 0.0001
3) a 666 (644–687) a < 0.0001
.95) a 0.92 (0.87-0.97) 0.030
2) a 193 (177–209) b < 0.0001
.39) a 0.29 (0.27-0.31) a, b < 0.0001
3) a 473 (452–495) b < 0.0001
.59) a 0.65 (0.62-0.69) a, b < 0.0001
ssary: a, significantly different from corresponding SHAM value; b, significantly
Table 4 Summary of analysis by linear mixed-effects
modelling of the time-dependent effects of trientine
treatment between Weeks 8 and 16 on indexes of cardiac
function in diabetic cardiomyopathy
Variable Treatment Week Treatment:Week
Body-weight (g) NS NS 0.035
Blood glucose (mM) NS NS NS
Heart rate (bpm) 0.098 NS NS
LVM (g) 0.023 NS 0.046
LVM/BW 0.096 0.0057 0.0077
CO (ml/min) 0.0009 NS < 0.0001
CO/LVM (ml/min.mg) 0.0001 0.0003 < 0.0001
LVEF (%) < 0.0001 < 0.0001 < 0.0001
LVEDV (μl) 0.018 0.0003 0.0091
LVEDV/LVM (μl/mg) 0.0041 NS 0.0013
LVESV (μl) 0.0013 < 0.0001 < 0.0001
LVESV/LVM (μl/mg) < 0.0001 < 0.0001 < 0.0001
Stroke Vol (μl) < 0.0001 0.10 < 0.0001
Stroke Vol/LVM (μl/mg) < 0.0001 0.0002 < 0.0001
Numbers are P-values derived from the fitting of LME models of the general
form (Variable ~ [treatment + week + treatment:week]) for each of the
indicated variables, wherein individual rats were considered to generate
random effects. Abbreviations: bpm, beats per minute; NS, not significant;
Treatment:Week, treatment-week interaction term.
Figure 2 Time- and treatment-dependent changes in blood glucose c
composition during the 16-week experimental period in groups of co
diabetic (n = 13) adult male rats. Drug treatment was initiated after the m
concentrations; B, Body-weight; C, Ratio of LV mass to body-weight (LVM/B
LV. Abbreviation: TETA, triethylenetetramine.
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increased at Week 8. At Week 16, the LVM/BW values
in DIA rats had increased further, consistent with wor-
sening of the relative LV hypertrophy (P < 0.001). Al-
though TETA-DIA rats had significantly lower LVM/BW
values than DIA at Week 16 (P < 0.05), their values were
still significantly higher than those of SHAM animals
(P < 0.001). Furthermore, the LVM/BW:time interaction
term for trientine treatment was significant (LME, P =
0.0077). Trientine thus ameliorated the relative cardiac
hypertrophy in diabetic rats.
Diabetes significantly lowered the percentage of car-
diac fat volume to myocardial volume in the LV (P <
0.001, Figure 2D), but trientine treatment did not alter
this variable. LV fat content in these diabetic rats was
significantly lower than that in the non-diabetic controls,
consistent with the severely insulin-deficient model of
diabetes employed in this study.
Effects of trientine treatment on left-ventricular function
Eight weeks diabetes significantly lowered many indexes
of LV function (Table 2) including LVEF values (P <
0.0001, Figure 3A), which worsened still further after the
second eight-week period of untreated disease (P <
0.0001). By contrast, eight weeks oral trientine treatmentoncentrations, body-weight, and indexes of LV size and
ntrol (n = 12), untreated-diabetic (n = 12) and trientine-treated
easurements of Week 8 (arrowed in A, B). A, Blood glucose
W); D, Percentage of cardiac fat volume to myocardial volume in the
Figure 3 Time- and treatment-dependent changes in cMRI-derived cardiac functional parameters during the 16-week experimental
period in groups of control (n = 12), untreated-diabetic (n = 12) and trientine-treated diabetic (n = 13) adult male rats. Drug treatment
was initiated after the measurements of Week 8 (arrowed in A, B): A, LV ejection fraction (LVEF); B, LV cardiac output (CO); C, Ratio of CO/LV mass
(CO/LVM); D, ratio of CO to body-weight (CO/BW). Abbreviation: TETA, triethylenetetramine.
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ing treatment, mean LVEF in trientine-treated diabetic
animals was equivalent to that in non-diabetic controls
(P > 0.05).
CO increased progressively in SHAM rats during the
study (P < 0.0001) as normal organ growth progressed,
but this increase did not occur in the DIA animals
(Figure 3B, Tables 1, 2 and 3). CO/LVM fell significantly
in both diabetic groups between Weeks 0 and 8 (P <
0.0001 in each) and further still in DIA animals between
Weeks 8 and 16 (P < 0.0001). The lack of normal increase
in CO is consistent with impaired growth in diabetic ani-
mals (Figure 2B). Eight weeks trientine treatment elevated
CO and CO/LVM in TETA-DIA rats to a level that was
significantly higher than in SHAM rats (P < 0.001) although
the CO of TETA-DIA animals remained significantly lower
than in SHAM rats (P < 0.01). Trientine also improved
other indexes that had previously been impaired by dia-
betes (Table 3), including stroke volume/LVM (P < 0.0001),
LVESV/LVM (P < 0.0001) and LVEDV/LVM (P = 0.030).
These data are consistent with drug-evoked improvements
in systolic and diastolic function.Effects of trientine treatment on cardiac output in an
ex vivo working-heart model
We also measured ex vivo CO at increasing preload
values to determine the relationship between in vivo and
ex vivo estimates of this variable in the same individuals
(Figure 4) [5]. Ex vivo CO-preload responses were con-
sistent with those we have previously reported [5,7]. In-
creasing preload elevated CO in all groups (all P <
0.0001). However, CO in untreated-diabetic rats did not
respond normally once preload values were increased
above the peri-physiological value of ~15 cmH2O, as
shown by flattening of the preload-CO curve above this
point (CO-preload:treatment interaction term in the
LME, P < 0.001). By contrast, the preload-CO curve in
trientine-treated diabetic animals was restored to nor-
mal, and was significantly improved compared with that
for untreated diabetic animals (CO-preload interaction
term in LME, P < 0.001). These findings are consistent
with the in vivo effects of trientine treatment on LVEF
and CO measured in the cMRI studies presented above.
Thus in vivo and ex vivo measurements of CO following
trientine treatment are mutually consistent in that both
Figure 4 Response of CO to increasing preload in ex vivo
isolated-perfused working hearts from experimental groups of
Control (n = 12), Untreated-Diabetic (n = 12) and Trientine-
treated Diabetic (n = 13) adult male rats.
Abbreviation: TETA, triethylenetetramine.
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ment in CO of diabetic animals.
Time-dependent effects of trientine on cardiac function
as determined by linear mixed-effects modeling
Linear mixed effects modelling (LME) “provides a gener-
ally flexible and powerful methodology for the analysis
of grouped data such as repeated measures” [31], and was
employed here to analyze the time-dependent effects of tri-
entine treatment on cardiac function. Significant treatment-
time interactions are considered to yield robust evidence of
therapeutic efficacy in such studies [32].
Results of LME-based analysis of the effects of trien-
tine treatment on indexes of cardiac function have been
shown in Table 4. Trientine treatment exerted a modest
time-dependent effect to ameliorate the effects of diabetes
on body-weight (P = 0.035) whereas it had no measurable
effect on blood glucose levels or heart rate. It significantly
improved LVM/BW (P = 0.0077), whereas the P-value cor-
responding to the corresponding non-indexed variable,
LVM, was 0.046: this contrast provides evidence that sup-
ports the use of LVM/BW as opposed to unindexed LVM
to measure time-dependent therapeutic effects on LV mass.
This finding is consistent with previous reports [5,12].
Trientine exerted substantive effects to improve CO,
CO/LVM, LVEF, stroke volume, and stroke volume indexed
to LVM (all P < 0.0001) (Table 4), consistent with results
from the corresponding ANOVA analysis. These effects
were caused by improvements in both systolic and diastolic
function: effects on LVESV and LVESV/LVM (both P <
0.0001) were arguably more prominent than those on
LVEDV (P = 0.0091) and LVEDV/LVM (P = 0.0013), whichmay point to a greater effect of trientine on systolic func-
tion in this study. Trientine treatment has previously
been shown to exert therapeutic effects on both diastolic
and systolic function in rats with diabetes-induced heart
failure [5].
Discussion
Here we have reported cMRI-derived measurements of
the effects of trientine treatment on cardiac function in
rats with established heart failure caused by diabetes.
Effects of diabetes on cardiac function were character-
ized, inter alia, by substantive impairment of functional
indexes including LVEF, CO/LVM (a measure of myo-
cardial efficiency [30,33]), LVEDV/LVM, LVESV/LVM,
stroke volume/LVM and elevated LVM/BW (the latter a
measure of relative LV hypertrophy). These findings are
consistent with prior reports and provide substantive
validation of the model used in the current studies [33].
Eight weeks trientine treatment significantly improved
cardiac function without modifying hyperglycemia, thus
effectively breaking the link between defective glucose
homeostasis and organ damage, and implicating defect-
ive copper regulation in the mechanism by which dia-
betes causes heart failure. Cardiac function improved in
every drug-treated rat, consistent with marked trientine-
evoked improvement in cardiac performance in rats with
established heart failure caused by diabetic cardiomyop-
athy. Furthermore, the beneficial effect of trientine treat-
ment on CO in these studies was consistent between the
cross-sectional and time-dependent in vivo cMRI ana-
lyses, and the subsequent cross-sectional ex vivo end-
point measurements in the same individuals.
Thus, trientine treatment substantively improved car-
diac function in this widely-used model of diabetes-
evoked heart failure. Previous studies have shown that
trientine treatment can improve LV hypertrophy, ex vivo
indexes of diastolic and systolic function, and numerous
cardiac biomarkers in animals with diabetes-induced
heart failure [6,34-36]. To date, however, there has been
no direct in vivo evidence that trientine can significantly
improve cardiac function in animals with established
heart failure. The current results are significant because
they provide robust support for ongoing development of
trientine treatment for the experimental treatment of
diabetic patients with heart failure, and validate the use
of cMRI to measure the responses of trientine treatment
in diabetic patients with impaired CO and LVEF.
Different values for LVEF have been reported in the
literature by different groups for normal rats or those
with heart failure [33,37-39]. Between-group differences
in reported values may be related to differences in rat
strains (for example Sprague–Dawley vs. Wistar), meth-
odological differences, or differences in the severity of
diabetes or the time that measurements were made after
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(Tables 1, 2 and 3) are consistent with data reported by
others in the literature, as measured by cMRI [38], PET
scanning [37] or echocardiography [37]. For example,
LVEF values comparable to ours in normal adult rats have
been reported that were determined by cMRI (79 ± 4%)
[38], cardiac PET scanning (83.2 ± 8.0%) [37] and echocar-
diography (81.6 ± 6.0%) [37]. The latter group also
reported values of LVEF in heart failure, of 54.6 ± 15.9% by
PET scanning and 54.2 ± 13.3% by echocardiography that
are also comparable to our measurements (Tables 2, 3, 4).
By contrast, others have reported moderately lower esti-
mates of LVEF in control (~64-67%) and diabetic (~42-
45%) rats [33,39]. Thus there is considerable variability in
published LVEF measurements in both normal rats and
those with heart failure, and our values lie in the mid-
range of reported values. In studies such as ours of the
reversal of disease effects, it is probably more important
that measurements in control, diabetic and drug-treated
diabetic animals were made by using a consistent ana-
lytical approach, as was done here. Furthermore, our
experiment employed significantly larger numbers of ani-
mals per group than were used by some of the others [33]
so the power of our study was considerably greater.
Treatment with the long-acting calcium channel blocker,
azelnidipine in STZ-diabetic rats has also been reported to
cause significant improvements in myocyte contractile
function, oxidative stress and myocardial apoptosis, which
were attributed to improved myocellular calcium homeo-
stasis [40]. However, there is compelling evidence that
impaired myocellular calcium handling does not explain
the impaired contractility of diabetic cardiomyopathy in
STZ-diabetic rats, which is actually attributable to LV
remodeling and consequential impairments in calcium
responsiveness [41]. Therefore, the actual mechanism
of the reported effects of azelnidipine [40] is by no
means clear.
The current results extend our previous work in non-
clinical models of diabetic organ damage [5,7,8,36,42,43]
and in clinical trials [10,13,44,45], where we have shown
that trientine is safe in both nondiabetic volunteers and
diabetic patients, and that it significantly improves anti-
oxidant defences and improves LVM in diabetic patients
with LVH [6,12]. Consistent with our prior results, trien-
tine treatment also improved diabetes-mediated cardiac
damage in Zucker diabetic rats, an animal model of
T2DM, whose metabolic disturbances were less severe
than those in the animals we studied here [35]. Taken
together with our nonclinical and clinical results, these
latter independent findings are consistent with our
current conclusions and provide further support for the
idea that trientine treatment can improve cardiac func-
tion in diabetic individuals with different degrees of
metabolic perturbation.The current study complements and extends our previous
studies in patients with T2DM and LV hypertrophy, in
whom 12-months trientine treatment significantly improved
LV mass indexed to body-surface area (LVMbsa) without ad-
verse remodeling consequences [12]. In that study, patients
had LVH and abnormal diastolic filling as demonstrated by
mitral inflow Doppler with preload reduction and LV ejec-
tion fraction ≥ 45% by echocardiography, with evidence of
diastolic dysfunction, and it remains to be determined
whether trientine treatment can improve indexes of cardiac
function in patients with established heart failure.
Previous mechanistic studies have indicated that trientine
decreases LVH by a combination of beneficial effects
through which it restores the integrity, inter alia, of ven-
tricular composition, cardiac myocellular actomyosin fila-
ments, mitochondria, and the ECM [5,7,43]. At the
molecular signaling level, these responses are mediated, at
least in part, by normalization of the myocardial and arter-
ial TGF-β/SMAD signaling pathways [7] with concurrent
bolstering of antioxidant defense mechanisms [36]. These
beneficial effects on tissue and organ structure/function are
probably mediated through trientine-evoked normalization
of copper regulation [6-8] with resulting lowering of oxida-
tive stress, and accompanying improvements in ROS me-
tabolism and mitochondrial function [36,43].
Of potential relevance to the current findings are results
from treatment with another copper chelator, tetrathio-
molybdate (TTM) that can inhibit acute inflammatory
responses in vivo [46]. In a recent study, TTM reportedly
inhibited vascular inflammation and atherosclerotic lesion
development in apolipoprotein-E deficient mice [47], rais-
ing the possibility that similar effects could also contribute
to the cardiovascular responses to trientine. However, in
this study, 10-weeks treatment with TTM induced signifi-
cant lowering of circulating ceruloplasmin levels, raising
the possibility that the reported findings could have been
confounded by concomitant copper deficiency, as signaled
by marked lowering of serum ceruloplasmin levels. By
contrast, under the conditions used in this study, trientine
does not cause copper deficiency [5,12].
What information is currently available about the dos-
age and tolerability of trientine in diabetes? In previous
nonclinical studies [5,7,34,35], trientine dosages have
been equivalent on a mg-per-kg basis in rats to those
employed in the current study and in our recently
reported 12-month clinical trial [12]. Trientine has been
well tolerated by diabetic and non-diabetic rats alike in
previous studies, in which it has typically been adminis-
tered orally in the drinking water for periods of between
6 and 8 weeks. It has also been well-tolerated by diabetic
patients in recent Phase 2 studies in one of which it was
administered at 1200 mg/d for 12 months [6,12]. Fur-
thermore, the trientine-treated patients in these studies
did not develop copper deficiency, as shown by levels of
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and ceruloplasmin [48]. Equivalent and higher doses were
also well tolerated by the non-diabetic volunteers in our
two recent Phase 1 pharmacokinetic-pharmacodynamic
studies [10,13]. In addition, comparable trientine dosages
have been used successfully for many years in the chronic
treatment of patients with Wilson’s disease [17,18]. An op-
timal trientine dosage for the treatment of heart failure in
diabetic patients is likely to lie in the region of 1200–
2400 mg/day (600–1200 mg b.i.d.) [6,10,12,13].
The current study has limitations. Trientine treatment
significantly improved cardiac function in diabetic rats
with established heart failure. Nevertheless, although sub-
stantively improved, their cardiac function was still mark-
edly impaired after eight weeks drug treatment compared
with non-diabetic controls. In comparison, T2DM patients
with LVH displayed on average a ~50% lowering of ele-
vated LVMbsa values after 12-months trientine treatment
[12]. Moreover, although CO was apparently fully restored
in this ex vivo study, comparison with the cMRI-based
measurements shows that the level of in vivo recovery was
less, at about ~30%. This difference may well reflect
greater sensitivity of the in vivo cMRI-based measure-
ments. Further studies will be required to determine the
maximal restoration of CO, CO/LVM, LVEF and stroke
volume/LVM values achievable by longer periods of trien-
tine treatment, and what length of treatment might be
required to achieve an optimal response. In addition, the
long-term sustainability of trientine-evoked improvements
in cardiac function also remains to be established. Finally,
it remains to be determined whether improvements in
functional parameters might herald lowered rates of
clinically-relevant cardiac endpoints and increased sur-
vival in patients with diabetes-associated heart failure.
Our measurements of myocardial fat indicate that the
model of severe STZ-evoked diabetes we employed here
is unlikely to yield useful information about copper/tri-
entine-myocardial lipid interactions. We have employed
the STZ-mediated model of diabetes-induced heart fail-
ure because it is reproducible and consistent in terms of
time of onset, progression, and severity, and its cardiac
structure/function responses are clearly consistent with
those in diabetic patients [5,12]. However, the metabolic
disturbance in this model is more akin to that in patients
with severe T1DM rather than T2DM, where the meta-
bolic disturbance is usually less severe. Trientine treat-
ment did not modify plasma lipid levels in rats with
hypercholesterolemia and hypertriglyceridemia caused
by diabetes [36]. We conclude that effects of trientine
on myocardial metabolism will need to be studied in
other nonclinical models of hyperlipidemic diabetes,
such as the Zucker diabetic rat, in which myocardial
lipid levels are elevated in untreated diabetic animals, in
order to better understand its effects on lipid regulation.Our measurements of simultaneous copper and triethyle-
netetramine concentrations in diabetic animals and humans
undergoing trientine treatment confirm that the molar tri-
entine free-base to Cu(II) ratio is consistently > > 1 in the
urine [14,44]. These findings, taken together with the
strong, selective binding of triethylenetetramine to Cu(II)
[9,11], are consistent with protection by the drug against
any copper toxicity that could otherwise be caused in the
body during trientine-mediated extraction of copper into
the urine. Trientine can thus effectively suppress Cu(II)-
mediated cytotoxicity. Biological effects that may explain
trientine’s therapeutic efficacy include its ability to elicit
structural and functional improvements in the cardiac myo-
cytes [5], the extracellular matrix [7] and cardiac mitochon-
dria [43], and to suppress oxidative stress, including that in
cardiovascular and renal tissues [8,13,36,49]. Current data
strongly support the view that trientine’s efficacy is under-
pinned in substantive part by its ability to suppress Cu(II)-
mediated oxidative stress and mitochondrial dysfunction
[36,43].
Administration of trientine and measurement of the
resulting urinary copper excretion unmasks the extent of
the copper overload in diabetes [5,6,12,14,45]. For example,
an oral challenge with trientine in diabetic patients revealed
a significant increase in chelated Cu(II) [5]. The presence of
elevated systemic copper following trientine administration
is an important sign because such copper is catalytically ac-
tive and therefore (presumably) capable of catalyzing the
formation of highly-destructive hydroxyl radicals from sub-
strates such as superoxide anion or hydrogen peroxide
[9,22]. Probing of diabetic animals and patients with various
applicable types of spectroscopy, including atomic absorp-
tion, atomic emission, ICP-MS, EPR and particle-induced
X-ray emission (PIXE), has demonstrated the presence of
copper excess in the whole body [5,6,12], urine, coronary
arteries [5], and kidneys [8]. Thus, defective copper regula-
tion could well make a major contribution to the causation
of oxidative stress in diabetes, which can thus be sup-
pressed by treatment using trientine with the outcome that
organ damage is thus substantively ameliorated.
How might particular organs be selectively targeted by
copper-mediated oxidative stress? Elevated pathogenetic
tissue binding of copper occurs in diabetes [5,6]. This
phenomenon could well be caused by copper-catalyzed
‘glycoxidation’ that mediates formation of advanced
glycation end-products (AGEs) and consequential AGE-
modification of susceptible amino-acid residues, particu-
larly lysine, arginine, histidine and cysteine, in long-lived
fibrous proteins such as connective-tissue collagens
[5,50-54]. Such AGE-modified amino-acid residues are
thought to act as endogenous chelators [9,21,55] that
can increase the copper content of organs such as the
coronary arteries and kidneys by binding increased amounts
of catalytically-active Cu(II), thereby focusing the related
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significance of these phenomena was not apparent before
we demonstrated suppression of diabetes-mediated organ
damage by Cu(II)-selective chelation [5-8,12,42,43].
What biological properties of copper underpin its
pathogenetic behaviour in diabetes? Most intracellular
copper is tightly bound and regulated by copper-binding
proteins [56], and intracellular free copper is essentially
undetectable [57]. Cu(II), which is present in urine from
drug-treated diabetic rats, is the most effective divalent
ion for binding to organic molecules and the main extra-
cellular copper ion, whereas Cu(I) predominates inside
cells [22]. Trientine binds Cu(II) less strongly than most
physiological copper-binding proteins [22]. These obser-
vations, taken together with our demonstration of the
prompt increase in Cu(II) excretion after oral trientine
administration in diabetic patients [5,6], and after injec-
tion into the coronary arteries in ex vivo cardiac pre-
parations from diabetic rats [5], indicate that this
increased Cu(II) is unlikely to be released acutely from
an intracellular pool. More likely, the Cu(II) is bound to
extracellular matrix (ECM) components, such as colla-
gen; because it is readily extracted by trientine, the
increased Cu(II) must be loosely bound and is therefore
the probable cause of the observed increase in oxidative
stress suppressible by trientine [36]. Importantly, con-
sistent with our recent X-ray crystallographic studies,
triethylenetetramine-binding to Cu(II) can suppresses its
catalytic activity, thus protecting the renal tubules from
the toxicity that could otherwise ensue.
There are several strong endogenous copper chelators
including spermine, spermidine and carnosine, which
are localized mainly within cells. There are no available
data known to us concerning their ability to extract sys-
temic copper into the urine in diabetes, or to treat dia-
betic cardiomyopathy. Spermine was reportedly highly
toxic when administered to chicks [58] and long-term
studies of its tolerability on administration to diabetic
rats are currently unavailable. Based on their structures
and related thermodynamic considerations, putrescine
(a diamine) and spermidine (a triamine) cannot bind cop-
per as strongly as triethylenetetramine (a tetraamine).
Much research would be required before the putative util-
ity of any of these endogenous polyamines in the treat-
ment of diabetic heart disease could be ascertained.
Some studies with clinically significant drugs used to
treat diabetic patients, such as metformin, pioglitazone
and some of the ARBs, have suggested that they are che-
lators that could exert their therapeutic effects through
copper chelation [59,60]. The strength of their copper-
binding ability appears to be relatively weak compared
with that of triethylenetetramine based on currently
available evidence. Moreover, there is no available in vivo
evidence to indicate that any of them acts by correctingthe dysregulated copper homeostasis that occurs in dia-
betes [6].
Mechanisms of action of trientine and metformin are
now briefly compared with respect to roles of copper.
Metformin is an anti-hyperglycemic biguanide drug that is
used extensively in the treatment of type 2 diabetes [61]. It
acts via AMP-activated protein kinase (AMPK), whose ac-
tivation is required for metformin’s inhibitory effect on
hepatic glucose production via inhibition of the diabetes-
mediated activation of the gluconeogenic genes phos-
phoenolpyruvate carboxykinase and glucose-6-phosphatase
[62-64]. The idea has recently been advanced that metfor-
min might function through binding to copper in locations
such as mitochondria [59]. As has been discussed above,
there is a substantive body of evidence linking defective
copper homeostasis to the pathobiology of diabetes and its
experimental treatment with trientine [9,21] which points
to major differences between the mechanisms of action of
the two drugs. For example, trientine does not lower blood
glucose in diabetic rats or patients, whereas glucose lower-
ing is metformin’s major therapeutic effect [5,12]. More-
over, in a study comparing patients with type-2 diabetes
and LV hypertrophy, who were taking standard thera-
peutic doses of metformin with or without trientine, LV
hypertrophy was unchanged in those taking metformin
only, but was substantively improved in the trientine-
treated patients [12]. Furthermore, trientine acts in vivo as
a chelator that removes excess Cu(II) from the body,
whereas patients treated with metformin have rates of
urinary copper excretion similar to basal (that is, un-
treated) values in diabetic patients [6,12]. Therefore, any
role played by copper binding in metformin’s mode of ac-
tion must be very different from that it plays for trientine.
In conclusion, eight weeks trientine treatment caused
significant improvement in numerous indexes of cardiac
function as determined by cMRI in a widely employed
nonclinical model of diabetes-induced heart failure, the
STZ-diabetic rat. These findings support and extend
previous studies in diabetic rats, and are consistent with
results from a recent Phase 2 trial of trientine treatment
in diabetic patients with LVH. The Cu(II)-selective che-
lator trientine is the first in a new class of orally-active
molecules with application in the experimental pharma-
cotherapy of the diabetic complications. The evidence
presented here supports the further clinical investigation
of trientine treatment in patients with diabetes and heart
failure.
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